The US Food and Drug Administration has approved SimpleScreen CRC, a blood-based colorectal cancer screening test developed by Freenome that Abbott will exclusively commercialize in the US for average-risk adults aged 45 and older. The test detects cell-free DNA signals linked to colorectal cancer.
（中文摘要：美国食品药品监督管理局（FDA）已批准由 Freenome 开发的基于血液的结直肠癌筛查检测 SimpleScreen CRC，雅培（Abbott）将在美国针对45岁及以上平均风险成年人进行独家商业化推广。该检测通过识别与结直肠癌相关的游离DNA信号进行筛查。）
